Bafna Pharmaceuticals Ltd vs Sai Parenterals Ltd Stock Comparison
Bafna Pharmaceuticals Ltd vs Sai Parenterals Ltd Stock Comparison
Last Updated on: May 08, 2026
Key Highlights
The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 132.65 as of 07 May 15:30
. The P/E Ratio of Bafna Pharmaceuticals Ltd is 0 as of March 2023
.The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023
. The Market Cap of Bafna Pharmaceuticals Ltd is ₹ 0 crore as of March 2023
.The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023
. The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The revenue of Sai Parenterals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The ebitda of Sai Parenterals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN%
The net profit of Sai Parenterals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990.
Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.
About Sai Parenterals Ltd
Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022.
Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.
FAQs for the comparison of Bafna Pharmaceuticals Ltd and Sai Parenterals Ltd
Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Sai Parenterals Ltd?
Market cap of Bafna Pharmaceuticals Ltd is 313 Cr while Market cap of Sai Parenterals Ltd is 2,199 Cr
What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Sai Parenterals Ltd?
The stock performance of Bafna Pharmaceuticals Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bafna Pharmaceuticals Ltd and Sai Parenterals Ltd?
As of May 8, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹132.65. On the other hand, Sai Parenterals Ltd stock price is INR ₹497.85.
How do dividend payouts of Bafna Pharmaceuticals Ltd and Sai Parenterals Ltd compare?
To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.